Despite showing promising results in Sjögren’s syndrome in open-label studies, abatacept has failed to show a significant benefit in the condition when compared with placebo in a randomised controlled trial. A Dutch study that compared 24 weeks of treatment with abatacept with placebo in 80 adults with primary Sjögren’s syndrome found no significant difference in ...
Hope dries up for abatacept in Sjögren’s syndrome
By Michael Woodhead
5 Feb 2020